21:02:42 EST Sat 04 Feb 2023
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

News for U:RVVTF from 2022-02-04 to 2023-02-03 - 31 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2023-02-03 06:00U:RVVTFNews ReleaseRevive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch
2023-01-19 16:50U:RVVTFNews ReleaseRevive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
2023-01-12 13:15U:RVVTFNews ReleaseRevive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
2023-01-12 06:00U:RVVTFNews ReleaseRevive Therapeutics Ltd. Closes $4.3 Million Offering
2023-01-09 15:34U:RVVTFNews ReleaseRevive Therapeutics Announces Publication Showing Bucillamine ¢ € ™s Potential Impact on COVID-19 Omicron Variants
2023-01-05 09:19U:RVVTFNews ReleaseRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
2022-12-22 14:01U:RVVTFNews ReleaseRevive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
2022-12-15 07:29U:RVVTFNews ReleaseRevive Therapeutics Ltd. Expands Life Offering to Quebec
2022-11-30 17:43U:RVVTFNews ReleaseRevive Therapeutics Ltd. Announces Offering of Up to $5 Million
2022-11-24 09:19U:RVVTFNews ReleaseRevive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
2022-11-22 09:20U:RVVTFNews ReleaseRevive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
2022-10-14 13:35U:RVVTFNews ReleaseRevive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
2022-10-06 10:18U:RVVTFNews ReleaseRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
2022-09-28 07:00U:RVVTFNews ReleaseRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
2022-09-16 06:00U:RVVTFNews ReleaseRevive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program
2022-09-14 06:00U:RVVTFNews ReleaseRevive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA
2022-08-16 06:00U:RVVTFNews ReleaseRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
2022-07-25 10:58U:RVVTFNews ReleaseRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
2022-06-24 11:41U:RVVTFNews ReleaseRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
2022-06-06 13:55U:RVVTFNews ReleaseRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
2022-05-31 07:00U:RVVTFNews ReleaseRevive Therapeutics Advances Inflammatory Liver Disorders Programs for Autoimmune Hepatitis and Liver Transplantation
2022-05-26 10:15U:RVVTFNews ReleaseRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
2022-05-16 10:49U:RVVTFNews ReleaseRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
2022-04-25 17:06U:RVVTFNews ReleasePharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update
2022-04-25 16:42U:RVVTFNews ReleaseRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
2022-04-18 09:43U:RVVTFNews ReleaseRevive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19
2022-04-11 17:54U:RVVTFNews ReleaseRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
2022-03-29 08:45U:RVVTFNews ReleaseRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
2022-02-24 08:00U:RVVTFNews ReleaseHAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research
2022-02-15 16:26U:RVVTFNews ReleaseRevive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation
2022-02-14 06:00U:RVVTFNews ReleaseRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19